The hemizygous 15q13.3 microdeletion is associated with increased risk of schizophrenia, epilepsy, autism and intellectual disability. A mouse model of the human 15q13.3 hemizygous microdeletion syndrome has previously been generated. Characterization of the model identified phenotypes related to schizophrenia and epilepsy. Human cases of homozygous microdeletion carriers have also been reported, all with severe impairments.